Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript

Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06.

Related Keywords

Canada ,Japan ,China ,United States ,Texas ,Chinese ,America ,American ,Bob Duggan ,Allen Yang ,Brad Canino ,Bradley Canino ,Manmeet Soni ,Mostafa Ronaghi ,Carter Gould ,Dave Gancarz ,Maky Zanganeh ,Us National Cancer Institute ,European Organization For Research ,Summit Therapeutics Inc ,Barclays ,Team Summit ,Nasdaq ,American Association Of Cancer Research ,American Society Of Clinical Oncology ,Society For Immunotherapy Of Cancer ,Summit Therapeutics ,Call Transcript May ,Summit Therapeutics First Quarter ,Chief Business ,Chief Executive Officer ,Chief Operating Officer ,Chief Financial Officer ,Chief Medical ,American Society ,Clinical Oncology ,European Lung Cancer Conference ,European Organization ,Cancer Institute ,American Association ,Cancer Research ,Targeted Therapies ,Lung Cancer ,Chief Technology Officer ,North America ,Akeso Phase ,Buying These ,Gas Stocks ,Reddit Stocks ,